peptide0 listings

Petrelintide

Petrelintide (ZP8396)

Long-acting amylin analog. Weight and metabolic research.

Weight researchMetabolic research

/ research index

The research base

Research Maturity

★★★☆☆

3/5 — Volume of studies

Evidence Strength

★★★☆☆

3/5 — Quality of evidence

Emerging long-acting amylin receptor agonist in development as a once-weekly monotherapy for weight research.

/ mechanism of action

How it works

Amylin receptor agonist. Promotes satiety and slows gastric emptying via amylin pathways, distinct from GLP-1.

/ research dosing

Common research protocols

Range

Escalating weekly doses (trial-stage, exact ladder emerging)

Frequency

Once weekly subcutaneous

Route

Subcutaneous

Cycle

Titrate up over weeks

Research notes

Amylin analogs are being studied as a gentler-tolerability alternative or complement to GLP-1 agonists. Dosing protocols still emerging from early-phase trials.

References

ClinicalTrials.gov NCT05silindrocebo (emerging)

FOR RESEARCH USE ONLY. Doses listed are compiled from published research literature, FDA-approved drug labels, and well-documented research community practice. Not medical advice.

/ standalone use

As a solo compound

Standalone amylin research; also studied alongside GLP-1 agonists.

Common pairings

+ Semaglutide + Retatrutide (GLP-3)

/ side effects

What to know

GI effects milder than GLP-1 class in early data; dose-dependent.

/ timeline

Realistic expectations

Effects build over weeks

FOR RESEARCH USE ONLY. Petrelintide is intended for laboratory research and not for human consumption.